Each material 8-K filed by an S&P 1500 company, read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (1506 companies, A–Z).
Arrowhead Pharmaceuticals refinanced its senior secured term loans on November 2, 2026, replacing a 15.0% payment-in-kind facility with a $400.0 million term loan at three-month Term SOFR plus 5.50% that matures November 2, 2031. The existing loans were repaid in full from cash on hand for an aggregate payoff of approximately $404.4 million, a discount of about $68 million from the 2.0x MOIC payment otherwise owed, and the new terms remove required prepayments from plozasiran sales and licensing proceeds. For shareholders, the filing shows lower interest cost, a longer maturity and fewer mandatory repayments, while the company now carries a $400.0 million secured obligation.
New $400.0 million senior secured term loan matures November 2, 2031, with interest at three-month Term SOFR (1.00% floor) plus 5.50%, versus a fixed 15.0% rate paid in kind on the retired loans
Existing loans repaid in full from cash on hand for an aggregate payoff of approximately $404.4 million, which included a discount of about $68 million from the 2.0x MOIC payment
Minimum unrestricted cash covenant reduced to $125.0 million from $150.0 million
New agreement no longer requires prepayment from plozasiran sales, royalties, milestones or pipeline monetizations; the filing says the terms are to be filed with the 10-Q for the quarter ended December 31, 2026
Pitney Bowes and its subsidiaries amended their credit agreement on September 29, 2026, reducing the interest rate margin on $585.5 million of tranche B term loans by 75 basis points. The company expects the change to cut annual interest expense by about $4 million, and the March 2032 maturity and other terms are unchanged.
Tranche B term loans outstanding of $585.5 million; margin cut from 375 to 300 basis points over Term SOFR, or 3.00%, and 2.00% for Base Rate loans
Company expects annual interest expense to fall by about $4 million based on the current principal balance
Maturity date (March 2032) and other loan terms unchanged, per the press release
S&P Global Ratings upgraded the issuer credit rating to 'BB-' from 'B+'
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by S&P 500, MidCap 400 and SmallCap 600 companies that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
The SEC filing feed is checked every hour on weekdays between 6 am and 10 pm Eastern; briefs follow within that hour or, when many filings arrive at once, later the same day.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.